Skip to content
Back to recalls
Drug FDA Class II Ongoing cGMP deviation

fentaNYL Citrate Injectable Solution in 0.9% Sodium Chloride, 1000 mcg/50mL (20 mcg per mL), well pharma of Houston, NDC 73702-203-65.

Wells Pharma of Houston LLC Published May 6, 2026

Risk level

Class II

May cause a temporary or reversible health problem; slight chance of serious harm.

Severity score 60/100

What should you do?

  • Check whether you have this product, using the lot codes, UPCs, and dates listed below.
  • Do not eat, serve, or sell the affected product.
  • Return it to the place of purchase for a refund, or throw it away in a sealed bag so people and animals can’t get to it.
  • Contact Wells Pharma of Houston LLC or your place of purchase with questions, and see the source record below for full details.
Reason for recall

cGMP deviations.

Affected products (1)

fentaNYL Citrate Injectable Solution in 0.9% Sodium Chloride, 1000 mcg/50mL (20 mcg per mL), well pharma of Houston, NDC 73702-203-65.

150 syringes

Lot codes: 022326203650432
Code info: Lot 022326203650432; Exp Date 06/25/2026

Affected areas

Nationwide

Timeline

  1. Initiated
    Apr 1, 2026
  2. Published
    May 6, 2026
Recall number
D-0506-2026
Agency
U.S. Food and Drug Administration
Country
US
Source data (openFDA JSON) About FDA enforcement reports

FDA records come from the openFDA drug enforcement-report dataset — the agency's full weekly enforcement list. Most entries are not issued as consumer press releases, so they won't appear on fda.gov/recalls or in a web search. The source record link above resolves this exact recall by its number.